Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Cash from Financing Activities (2021 - 2025)

Biote has reported Cash from Financing Activities over the past 5 years, most recently at -$9.1 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$9.1 million for Q4 2025, up 8.08% from a year ago — trailing twelve months through Dec 2025 was -$43.6 million (up 42.75% YoY), and the annual figure for FY2025 was -$43.6 million, up 42.75%.
  • Cash from Financing Activities for Q4 2025 was -$9.1 million at Biote, down from -$4.9 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for BTMD hit a ceiling of $319.0 million in Q1 2021 and a floor of -$329.5 million in Q2 2021.
  • Median Cash from Financing Activities over the past 5 years was -$5.0 million (2023), compared with a mean of -$4.5 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 125.57% in 2022 and later tumbled 1065.92% in 2024.
  • Biote's Cash from Financing Activities stood at -$5.2 million in 2021, then increased by 23.39% to -$4.0 million in 2022, then surged by 36.49% to -$2.5 million in 2023, then plummeted by 293.43% to -$9.9 million in 2024, then increased by 8.08% to -$9.1 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$9.1 million (Q4 2025), -$4.9 million (Q3 2025), and -$27.2 million (Q2 2025) per Business Quant data.